ArticleAlimentary pharmacology & therapeutics2014
Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases.
Article in Alimentary pharmacology & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Diet and inflammatory bowel disease: The Asian Working Group guidelines.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Guideline
- Pooled it
- Pooled it
- Effect of Vitamin D Supplementation on Faecal Microbiota: A Randomised Clinical Trial.Nutrients · 2019Trial
- Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial.The Journal of clinical endocrinology and metabolism · 2016Trial
- Serum 25-hydroxyvitamin D levels andArchives of medical science : AMS · 2026Article
- Molecular Mechanisms and Clinical Implications of Complex Prehabilitation in Colorectal Cancer Surgery: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Global Patterns ofCrohn's & colitis 360 · 2025Article
- A nomogram for predicting the risk ofFrontiers in pediatrics · 2025Article
- Increasing ratio of opportunistic infections associated with sunshine exposure and economic level burdening Chinese inflammatory bowel disease hospitalized patients: the first nationwide survey from 2014 to 2019.BMC public health · 2024Article
- Serum Vitamin D Level and Gut Microbiota in Women.Healthcare (Basel, Switzerland) · 2023Article
- Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients.Cancers · 2022Review
- Vitamin DAutophagy · 2022Article
- Host and Clostridioides difficile-Response Modulated by Micronutrients and Glutamine: An Overview.Frontiers in nutrition · 2022Review
- Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease.Digestive diseases and sciences · 2021Article
- Difference in Vitamin D Levels Between Children withPediatric gastroenterology, hepatology & nutrition · 2021Article
- Vitamin D and Streptococci: The Interface of Nutrition, Host Immune Response, and Antimicrobial Activity in Response to Infection.ACS infectious diseases · 2020Review
- Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.International journal of molecular sciences · 2020Review
- Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os.Crohn's & colitis 360 · 2020Article
- Effects of Vitamin D Supplementation on Inflammation, Colonic Cell Kinetics, and Microbiota in Colitis: A Review.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundPatients with inflammatory bowel diseases (IBD) have an increased risk of clostridium difficile infection (CDI). Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins. Plasma calcifediol [25(OH)D] stimulates production of cathelicidins.
aimTo examine the association between plasma 25(OH)D and CDI in patients with IBD.
methodsFrom a multi-institutional IBD cohort, we identified patients with at least one measured plasma 25(OH)D. Our primary outcome was development of CDI. Multivariate logistic regression models adjusting for potential confounders were used to identify independent effect of plasma 25(OH)D on risk of CDI.
resultsWe studied 3188 IBD patients of whom 35 patients developed CDI. Patients with CDI-IBD were older and had greater co-morbidity. The mean plasma 25(OH)D level was significantly lower in patients who developed CDI (20.4 ng/mL) compared to non-CDI-IBD patients (27.1 ng/mL) (P = 0.002). On multivariate analysis, each 1 ng/mL increase in plasma 25(OH)D was associated with a 4% reduction in risk of CDI (OR 0.96, 95% CI 0.93-0.99, P = 0.046). Compared to individuals with vitamin D >20 ng/mL, patients with levels <20 ng/mL were more likely to develop CDI (OR 2.27, 95% CI 1.16-4.44). The mean plasma 25(OH)D in patients with CDI who subsequently died was significantly lower (12.8 ± 8.1 ng/mL) compared to those who were alive at the end of follow-up (24.3 ± 13.2 ng/mL) (P = 0.01).
conclusionsHigher plasma calcifediol [25(OH)D] is associated with reduced risk of C. difficile infection in patients with IBD. Further studies of therapeutic supplementation of vitamin D in patients with inflammatory bowel disease and C. difficile infection may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.